Hemostemix wins full Bahamas LARTA approval for VesCell Phase 1 study
Bitget2026/10/07 18:37Hemostemix received full approval from The Bahamas’ National Longevity and Regenerative Therapy Board for a commercial Phase 1 VesCell study. The clearance includes ethics approval, enabling trials targeting angina, vascular dementia, and pain within The Bahamas’ regenerative-medicine framework. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hemostemix Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202610071437NEWSFILECNPR____20261007_317952_1) on October 07, 2026, and is solely responsible for the information contained therein.
- Hemostemix received full approval from The Bahamas’ National Longevity and Regenerative Therapy Board for a commercial Phase 1 VesCell study.
- The clearance includes ethics approval, enabling trials targeting angina, vascular dementia, and pain within The Bahamas’ regenerative-medicine framework.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SNT Holdings, Related Party Raise Combined Stake in SNTEnergy to 55.75% From 52.75%
Cold wave and rising fuel costs drive electricity prices in northeastern Japan and Tokyo to a four-year high
Japan's spot electricity prices surged to multi-year highs over the weekend.
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail
Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.
Canaccord Genuity: Lowers Oklo's target price to $66
Crypto prices
More
